346 related articles for article (PubMed ID: 33924994)
1. The Role of Wild-Type RAS in Oncogenic RAS Transformation.
Sheffels E; Kortum RL
Genes (Basel); 2021 Apr; 12(5):. PubMed ID: 33924994
[TBL] [Abstract][Full Text] [Related]
2. Oncogenic RAS isoforms show a hierarchical requirement for the guanine nucleotide exchange factor SOS2 to mediate cell transformation.
Sheffels E; Sealover NE; Wang C; Kim DH; Vazirani IA; Lee E; M Terrell E; Morrison DK; Luo J; Kortum RL
Sci Signal; 2018 Sep; 11(546):. PubMed ID: 30181243
[TBL] [Abstract][Full Text] [Related]
3. Anchorage-independent growth conditions reveal a differential SOS2 dependence for transformation and survival in
Sheffels E; Sealover NE; Theard PL; Kortum RL
Small GTPases; 2021 Jan; 12(1):67-78. PubMed ID: 31062644
[TBL] [Abstract][Full Text] [Related]
4. Interactions between wild-type and mutant Ras genes in lung and skin carcinogenesis.
To MD; Rosario RD; Westcott PM; Banta KL; Balmain A
Oncogene; 2013 Aug; 32(34):4028-33. PubMed ID: 22945650
[TBL] [Abstract][Full Text] [Related]
5. A requirement for wild-type Ras isoforms in mutant KRas-driven signalling and transformation.
Bentley C; Jurinka SS; Kljavin NM; Vartanian S; Ramani SR; Gonzalez LC; Yu K; Modrusan Z; Du P; Bourgon R; Neve RM; Stokoe D
Biochem J; 2013 Jun; 452(2):313-20. PubMed ID: 23496764
[TBL] [Abstract][Full Text] [Related]
6. Targeting the RAS-dependent chemoresistance: The Warburg connection.
Serna-Blasco R; Sanz-Álvarez M; Aguilera Ó; García-Foncillas J
Semin Cancer Biol; 2019 Feb; 54():80-90. PubMed ID: 29432815
[TBL] [Abstract][Full Text] [Related]
7. Isoform-specific Ras signaling is growth factor dependent.
Hood FE; Klinger B; Newlaczyl AU; Sieber A; Dorel M; Oliver SP; Coulson JM; Blüthgen N; Prior IA
Mol Biol Cell; 2019 Apr; 30(9):1108-1117. PubMed ID: 30785867
[TBL] [Abstract][Full Text] [Related]
8. Evaluating The Role Of Nitric Oxide Synthase In Oncogenic Ras-Driven Tumorigenesis.
Counter C
Redox Biol; 2015 Aug; 5():417. PubMed ID: 28162280
[TBL] [Abstract][Full Text] [Related]
9. Breaking Oncogene Addiction: Getting RTK/RAS-Mutated Cancers off the SOS.
Sheffels E; Kortum RL
J Med Chem; 2021 May; 64(10):6566-6568. PubMed ID: 33961431
[TBL] [Abstract][Full Text] [Related]
10. The impact of oncogenic RAS on redox balance and implications for cancer development.
Lim JKM; Leprivier G
Cell Death Dis; 2019 Dec; 10(12):955. PubMed ID: 31852884
[TBL] [Abstract][Full Text] [Related]
11. The renewed battle against RAS-mutant cancers.
Zhang F; Cheong JK
Cell Mol Life Sci; 2016 May; 73(9):1845-58. PubMed ID: 26892781
[TBL] [Abstract][Full Text] [Related]
12. Unique dependence on Sos1 in
You X; Kong G; Ranheim EA; Yang D; Zhou Y; Zhang J
Blood; 2018 Dec; 132(24):2575-2579. PubMed ID: 30377195
[TBL] [Abstract][Full Text] [Related]
13. Reduced HRAS G12V-Driven Tumorigenesis of Cell Lines Expressing KRAS C118S.
Huang L; Counter CM
PLoS One; 2015; 10(4):e0123918. PubMed ID: 25902334
[TBL] [Abstract][Full Text] [Related]
14. The role of wild type RAS isoforms in cancer.
Zhou B; Der CJ; Cox AD
Semin Cell Dev Biol; 2016 Oct; 58():60-9. PubMed ID: 27422332
[TBL] [Abstract][Full Text] [Related]
15. Genomic classification of serous ovarian cancer with adjacent borderline differentiates RAS pathway and TP53-mutant tumors and identifies NRAS as an oncogenic driver.
Emmanuel C; Chiew YE; George J; Etemadmoghadam D; Anglesio MS; Sharma R; Russell P; Kennedy C; Fereday S; Hung J; Galletta L; Hogg R; Wain GV; Brand A; Balleine R; MacConaill L; Palescandolo E; Hunter SM; Campbell I; Dobrovic A; Wong SQ; Do H; Clarke CL; Harnett PR; Bowtell DD; deFazio A;
Clin Cancer Res; 2014 Dec; 20(24):6618-30. PubMed ID: 25316818
[TBL] [Abstract][Full Text] [Related]
16. RAS-mediated oncogenic signaling pathways in human malignancies.
Khan AQ; Kuttikrishnan S; Siveen KS; Prabhu KS; Shanmugakonar M; Al-Naemi HA; Haris M; Dermime S; Uddin S
Semin Cancer Biol; 2019 Feb; 54():1-13. PubMed ID: 29524560
[TBL] [Abstract][Full Text] [Related]
17. RAS, wanted dead or alive: Advances in targeting RAS mutant cancers.
Stalnecker CA; Der CJ
Sci Signal; 2020 Mar; 13(624):. PubMed ID: 32209699
[TBL] [Abstract][Full Text] [Related]
18. Non-Redundant and Overlapping Oncogenic Readouts of Non-Canonical and Novel Colorectal Cancer KRAS and NRAS Mutants.
Alcantara KMM; Malapit JRP; Yu RTD; Garrido JAMG; Rigor JPT; Angeles AKJ; Cutiongco-de la Paz EM; Garcia RL
Cells; 2019 Dec; 8(12):. PubMed ID: 31816869
[TBL] [Abstract][Full Text] [Related]
19. CPI-17 drives oncogenic Ras signaling in human melanomas via Ezrin-Radixin-Moesin family proteins.
Riecken LB; Zoch A; Wiehl U; Reichert S; Scholl I; Cui Y; Ziemer M; Anderegg U; Hagel C; Morrison H
Oncotarget; 2016 Nov; 7(48):78242-78254. PubMed ID: 27793041
[TBL] [Abstract][Full Text] [Related]
20. Oncogenic Ras Isoforms Signaling Specificity at the Membrane.
Nussinov R; Tsai CJ; Jang H
Cancer Res; 2018 Feb; 78(3):593-602. PubMed ID: 29273632
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]